ATF4通过诱导SLC7A11(xCT)阻断应激相关铁死亡以抑制肝癌发生
研究利用肝细胞特异性ATF4缺陷的MUP-uPA小鼠高脂饮食诱导NASH相关HCC及二乙基亚硝胺致癌模型,发现ATF4缺失虽抑制肝脂肪变,但增加铁死亡易感性并加速HCC发生;过表达SLC7A11可逆转该表型,铁死亡抑制剂减少肝损伤和炎症;人HCC和NASH肝组织中ATF4与SLC7A11表达正相关。
要点
- 肝细胞ATF4缺失抑制肝脂肪变但增加铁死亡易感性,加速HCC发生。
- 过表达单一ATF4靶基因Slc7a11可逆转铁死亡易感性和肝癌发生。
- 铁死亡抑制剂减少肝损伤和炎症。
核心结论
- ATF4在正常肝细胞中通过维持谷胱甘肽产生抑制铁死亡依赖性炎症性细胞死亡,发挥重要保护作用,尽管在已形成的HCC中ATF4上调。
研究设计与样本
- 肝细胞特异性ATF4缺陷的MUP-uPA小鼠(MUP-uPA/Atf4Δhep)与对照MUP-uPA/Atf4F/F小鼠喂食高脂饮食诱导NASH相关HCC。
- Atf4F/F和Atf4Δhep小鼠注射二乙基亚硝胺建立致癌物诱导HCC模型。
- 进行组织学、生化和RNA测序分析,并在ATF4缺陷原代肝细胞和小鼠肝脏中重建SLC7A11以研究其对铁死亡和HCC发展的影响。
主要发现
- 肝细胞ATF4缺失抑制肝脂肪变,但增加铁死亡易感性,导致HCC发展加速。
- 过表达单一ATF4靶基因Slc7a11(编码胱氨酸/谷氨酸逆向转运体xCT亚基)可逆转铁死亡易感性和肝癌发生。
- 铁死亡抑制剂减少肝损伤和炎症。
- 人HCC和NASH患者肝脏中ATF4与SLC7A11表达呈正相关。
临床怎么用
- 作者认为铁死亡抑制剂或ATF4激活剂可能延缓HCC发生。
- 作者指出这些发现强化了良性脂肪变可能具有保护性的观点,除非伴随应激诱导的肝损伤,否则不增加癌症风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC), a leading cause of cancer-related death, is associated with viral hepatitis, non-alcoholic steatohepatitis (NASH), and alcohol-related steatohepatitis, all of which trigger endoplasmic reticulum (ER) stress, hepatocyte death, inflammation, and compensatory proliferation. Using ER stress-prone MUP-uPA mice, we established that ER stress and hypernutrition cooperate to cause NASH and HCC, but the contribution of individual stress effectors, such as activating transcription factor 4 (ATF4), to HCC and their underlying mechanisms of action remained unknown. METHODS: Hepatocyte-specific ATF4-deficient MUP-uPA mice (MUP-uPA/Atf4Δhep) and control MUP-uPA/Atf4F/F mice were fed a high-fat diet to induce NASH-related HCC, and Atf4F/F and Atf4Δhep mice were injected with diethylnitrosamine to model carcinogen-induced HCC. Histological, biochemical, and RNA-sequencing analyses were performed to identify and define the role of ATF4-induced solute carrier family 7a member 11 (SLC7A11) expression in hepatocarcinogenesis. Reconstitution of SLC7A11 in ATF4-deficient primary hepatocytes and mouse livers was used to study its effects on ferroptosis and HCC development. RESULTS: Hepatocyte ATF4 ablation inhibited hepatic steatosis, but increased susceptibility to ferroptosis, resulting in accelerated HCC development. Although ATF4 activates numerous genes, ferroptosis susceptibility and hepatocarcinogenesis were reversed by ectopic expression of a single ATF4 target, Slc7a11, coding for a subunit of the cystine/glutamate antiporter xCT, which is needed for glutathione synthesis. A ferroptosis inhibitor also reduced liver damage and inflammation. ATF4 and SLC7A11 amounts were positively correlated in human HCC and livers of patients with NASH. CONCLUSIONS: Despite ATF4 being upregulated in established HCC, it serves an important protective function in normal hepatocytes. By maintaining glutathione production, ATF4 inhibits ferroptosis-dependent inflammatory cell death, which is known to promote compensatory proliferation and hepatocarcinogenesis. Ferroptosis inhibitors or ATF4 activators may also blunt HCC onset. IMPACT AND IMPLICATIONS: Liver cancer or hepatocellular carcinoma (HCC) is associated with multiple aetiologies. Most HCC aetiologies cause hepatocyte stress and death, as well as subsequent inflammation, and compensatory proliferation, thereby accelerating HCCdevelopment. The contribution of individual stress effectors to HCC and their underlying mechanisms of action were heretofore unknown. This study shows that the stress-responsive transcription factor ATF4 blunts liver damage and cancer development by suppressing iron-dependent cell death (ferroptosis). Although ATF4 ablation prevents hepatic steatosis, it also increases susceptibility to ferroptosis, due to decreased expression of the cystine/glutamate antiporter SLC7A11, whose expression in human HCC and NASH correlates with ATF4. These findings reinforce the notion that benign steatosis may be protective and does not increase cancer risk unless accompanied by stress-induced liver damage. These results have important implications for prevention of liver damage and cancer.
引用
- He F, Zhang P, Liu J, et al. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J Hepatol. 2023. PMID: 36996941. doi:10.1016/j.jhep.2023.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。